INT159278

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2006
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 2.11
Pain Relevance 1.70

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endoplasmic reticulum (Ugt1a6) enzyme binding (Ugt1a6) protein complex (Ugt1a6)
Anatomy Link Frequency
liver 1
kidney 1
Ugt1a6 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
depression 6 98.40 Very High Very High Very High
adenocard 223 98.00 Very High Very High Very High
agonist 109 95.00 High High
Morphine 4 94.76 High High
Paracetamol 4 88.68 High High
antagonist 29 75.56 Quite High
Hippocampus 4 73.28 Quite High
Pain 2 69.28 Quite High
Spinal cord 6 34.96 Quite Low
cva 9 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 16 99.98 Very High Very High Very High
Depression 6 98.40 Very High Very High Very High
Hepatocellular Cancer 2 91.56 High High
Fibrosarcoma 3 90.32 High High
Cancer 16 82.80 Quite High
Convulsion 2 75.36 Quite High
Acute-phase Reaction 2 75.00 Quite High
Osteoporosis 15 71.28 Quite High
Pain 2 69.28 Quite High
Cognitive Disorder 3 65.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Endotoxin administration was associated with a time-dependent decrease in UGT1A1, UGT1A6, UGT2B1, and UGT2B3 mRNA levels in liver and kidney tissues.
Negative_regulation (decrease) of UGT1A6 in kidney
1) Confidence 0.51 Published 2008 Journal Drug Metab Lett Section Abstract Doc Link 19356101 Disease Relevance 0.07 Pain Relevance 0.31
Endotoxin administration was associated with a time-dependent decrease in UGT1A1, UGT1A6, UGT2B1, and UGT2B3 mRNA levels in liver and kidney tissues.
Negative_regulation (decrease) of UGT1A6 in liver
2) Confidence 0.17 Published 2008 Journal Drug Metab Lett Section Abstract Doc Link 19356101 Disease Relevance 0.07 Pain Relevance 0.31
There was a beneficial effect on Apo A1, a small decrease in HDL-cholesterol in one lasofoxifene group, and a 0.5 to 7.3% increase in median triglyceride levels.
Negative_regulation (decrease) of A1 associated with disorder of lipid metabolism
3) Confidence 0.03 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2773750 Disease Relevance 1.13 Pain Relevance 0.07
Similar results have also been observed using organotypic slices, where the short-term depression of a single CA1 pathway (with a 10 Hz, 5 s stimulation) was partly reversed by blocking A1 receptors [6].
Negative_regulation (blocking) of A1 associated with depression
4) Confidence 0.03 Published 2008 Journal Current Neuropharmacology Section Body Doc Link PMC2701281 Disease Relevance 0.44 Pain Relevance 0.68
This is similar to the effect of A1, B1 (not shown) and C1 extract observed herein.
Negative_regulation (effect) of A1
5) Confidence 0.03 Published 2006 Journal Evidence-based Complementary and Alternative Medicine Section Body Doc Link PMC1513146 Disease Relevance 0.39 Pain Relevance 0
Stiles and co-workers were among the first to study A1 receptor desensitization in detail (1991).
Negative_regulation (desensitization) of A1
6) Confidence 0.02 Published 2007 Journal Purinergic Signal Section Body Doc Link PMC2245999 Disease Relevance 0 Pain Relevance 0.32

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox